167 related articles for article (PubMed ID: 27733172)
1. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
[TBL] [Abstract][Full Text] [Related]
2. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
3. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
4. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
Liu X; Chong Y; Liu H; Han Y; Niu M
Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
[TBL] [Abstract][Full Text] [Related]
5. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
[TBL] [Abstract][Full Text] [Related]
6. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.
Shan Q; Li S; Cao Q; Yue C; Niu M; Chen X; Shi L; Li H; Gao S; Liang J; Yu R; Liu X
Korean J Physiol Pharmacol; 2020 May; 24(3):193-201. PubMed ID: 32392910
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
Pathria G; Wagner C; Wagner SN
J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
[TBL] [Abstract][Full Text] [Related]
9. Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.
Liu X; Tu Y; Wang Y; Zhou D; Chong Y; Shi L; Liu G; Zhang X; Wu S; Li H; Gao S; Niu M; Yu R
Cancer Cell Int; 2020; 20():97. PubMed ID: 32256206
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
[TBL] [Abstract][Full Text] [Related]
11. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
Zhang K; Wang M; Tamayo AT; Shacham S; Kauffman M; Lee J; Zhang L; Ou Z; Li C; Sun L; Ford RJ; Pham LV
Exp Hematol; 2013 Jan; 41(1):67-78.e4. PubMed ID: 22986101
[TBL] [Abstract][Full Text] [Related]
12. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
13. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
[TBL] [Abstract][Full Text] [Related]
14. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
15. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
[TBL] [Abstract][Full Text] [Related]
16. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
[TBL] [Abstract][Full Text] [Related]
17. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
Tai YT; Landesman Y; Acharya C; Calle Y; Zhong MY; Cea M; Tannenbaum D; Cagnetta A; Reagan M; Munshi AA; Senapedis W; Saint-Martin JR; Kashyap T; Shacham S; Kauffman M; Gu Y; Wu L; Ghobrial I; Zhan F; Kung AL; Schey SA; Richardson P; Munshi NC; Anderson KC
Leukemia; 2014 Jan; 28(1):155-65. PubMed ID: 23588715
[TBL] [Abstract][Full Text] [Related]
18. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.
Shen A; Wang Y; Zhao Y; Zou L; Sun L; Cheng C
Neurosurgery; 2009 Jul; 65(1):153-9; discussion 159-60. PubMed ID: 19574837
[TBL] [Abstract][Full Text] [Related]
19. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
[TBL] [Abstract][Full Text] [Related]
20. miR-215 functions as an oncogene in high-grade glioma by regulating retinoblastoma 1.
Meng X; Shi B
Biotechnol Lett; 2017 Sep; 39(9):1351-1358. PubMed ID: 28573541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
